Sun Pharmaceutical Industries Ltd 2023 AR2
The report highlights Sun Pharmaceutical Industries Limited's financial and operational performance for the fiscal year 2022-2023. Key achievements include a 12.6% increase in gross sales to INR 433 billion and a 29.3% growth in the global specialty business, reaching USD 871 million. The company expanded its dermatology portfolio through the acquisition of Concert Pharmaceuticals, Inc. and launched Sezaby in the US. On the sustainability front, the company reduced its Scope 1 and Scope 2 greenhouse gas emissions by 10.4% and water consumption by 17.7% compared to the 2020 baseline.
Company: Sun Pharmaceutical Industries Ltd
Sector: Manufacturing
Country: India
Year: 2023
Type: AR2
Pages: 308
Back to company
Sun Pharmaceutical Industries Ltd
Annual Report
The report highlights Sun Pharmaceutical Industries Limited's financial and operational performance for the fiscal year 2022-2023. Key achievements include a 12.6% increase in gross sales to INR 433 billion and a 29.3% growth in the global specialty business, reaching USD 871 million. The company expanded its dermatology portfolio through the acquisition of Concert Pharmaceuticals, Inc. and launched Sezaby in the US. On the sustainability front, the company reduced its Scope 1 and Scope 2 greenhouse gas emissions by 10.4% and water consumption by 17.7% compared to the 2020 baseline.
Sign in for free to access detailed sustainability data, reporting standards, and ESG metrics.
Document Details
Report Year
2023
Reporting Period
Apr 1, 2022 - Mar 31, 2023
Fiscal Year
2023
Type
Annual Report with Sustainability Disclosures
Language
English
Pages
File Size
Standards & Assurance
Reporting Standards
Materiality Assessment
Assurance
ESG Data?Experimental: AI-extracted data, may contain inaccuracies
Emissions
Scope 1:
Scope 2:
Energy Consumption
Renewable Energy
Water Consumption
Total Waste
Women on Board
Women in Management
Workplace Fatalities
Employees